Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06417177 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jul 2026 → Dec 2026
See other at-risk trials from University of Missouri-Columbia

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 2026 to Dec 2026v6
  2. Primary and study completion dates: Jul 2025 to Jul 2026v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2024 to Jun 3, 2024
    v3
  5. Interventions: Placebo (Drug), Propranolol (Drug), Vibegron (Drug) to Gemtesa (Drug), Placebo (Drug), Propranolol (Drug)
    • Eligibility criteria shortened, about 2 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.
Trial Details
NCT Number NCT06417177
Lead Sponsor University of Missouri-Columbia
Conditions
(from sponsor)		 Aging, Menopause, Hypoxia, Vasodilation
Related terms Aneurysm, Hypoxia
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov